UChicago Medicine Comprehensive Cancer Center
Ryan Merkow MD and Patient
Ryan Merkow, MD, MS, holds an HAI pump as he discusses the procedure. Dr. Merkow leads a team of surgical oncologists, medical oncologists, pathologists and other specialists who provide this advanced treatment for patients with cancer.

What is hepatic artery infusion (HAI)?

Hepatic artery infusion (also called hepatic arterial infusion pump chemotherapy, or HAI) is an innovative treatment for patients with certain metastatic colorectal and bile duct cancers that affect the liver. It’s a powerful tool for doctors to use to treat liver tumors and to further customize treatment plans.

With the help of an implantable pump, HAI delivers high doses of chemotherapy directly to the liver. It shrinks tumors with fewer side effects than traditional chemotherapy given through a vein.

Appointments: 1-855-702-8222

An Innovative Treatment from a Leading Cancer Center

The University of Chicago Medicine is home to a National Cancer Institute-designated Comprehensive Cancer Center, where patients have access to HAI as well as other innovative treatments and clinical trials that are not widely available at other hospitals.

The University of Chicago Medicine is among a select number of hospitals in the country to offer this advanced treatment. HAI is part of our highly respected, team-based Regional Cancer Therapies Program.

Hepatic Artery Infusion (HAI) Pump Chemotherapy for Liver Metastases

Hepatic Artery Infusion Pump: What to Expect

Understanding key facts can help you feel ready and informed for your HAI treatment journey. If you have more questions, your care team is available to support you.

An Innovator in Hepatic Artery Infusion Research

At UChicago Medicine, our team is conducting a clinical trial of HAI for patients with metastatic colorectal cancer that has spread to the liver but who are not candidates for surgery. We also plan to study other chemotherapy drugs to use with the pump as well as other types of patients who might benefit from this treatment.

UChicago Medicine is also part of an international consortium of academic medical centers studying survival, quality of life and other outcomes for patients who have been treated with HAI. Through this collaborative effort, we aim to make HAI as safe and effective as possible and more widely available to patients who could benefit. 

Hepatic Artery Infusion Team